abrdn Life Sciences Investors Q1 2026 Commentary
2026-05-20 11:40:00 ET
Fund performance
The equity portion of the Fund rose (gross of fees) but underperformed its benchmark, the NASDAQ Biotechnology Index. 1 ...
Read the full article on Seeking Alpha
For further details see:
abrdn Life Sciences Investors Q1 2026 CommentaryNASDAQ: HQL
HQL Trading
-1.73% G/L:
$17 Last:
69,473 Volume:
$17.25 Open:



